Toronto General Hospital, University of Toronto, Toronto, ON, Canada.
Aarhus University Hospital, Aarhus, Denmark.
Liver Int. 2018 Oct;38(10):1785-1792. doi: 10.1111/liv.13738. Epub 2018 Mar 31.
BACKGROUND & AIMS: Acute episodes of renal dysfunction or acute kidney injury (AKI) in cirrhotic patients with ascites are mostly precipitated by an acute event. The prevalence of un-precipitated AKI in stable ascitic cirrhotic patients is unknown. The aims of this study were to determine (i) the prevalence of un-precipitated AKI in stable cirrhotics with ascites and (ii) any predictive factors for its development.
A total of 1115 stable cirrhotic patients with mild liver and renal dysfunction but varying degrees of ascites severity from 3 previous satavaptan vs placebo randomized controlled trials (Group A, ascites requiring diuretics but not paracentesis; Group B, ascites requiring frequent paracentesis; Group C, refractory ascites) were included. AKI was diagnosed when there was either an increase of ≥0.3 mg/dL in ≤48 hours or a 50% increase in serum creatinine, and staged according to the fold increase of the serum creatinine. Two serum creatinine levels measured maximally 7 days apart at screening and at randomization of the satavaptan studies with no acute intervening events were used.
The prevalence of un-precipitated AKI was 1.8% overall, with the prevalence rising with increasing severity of ascites. Ninety-five per cent of cases were stage 1, with 15% progression rate, 3 reaching the severity of type 1 acute hepatorenal syndrome. Ascites severity was the most powerful predictor for un-precipitated AKI development, which did not predict overall mortality.
Increased prevalence of AKI with more severe ascites despite minimal baseline liver and renal dysfunction suggests that frequent monitoring of renal function in these patients is mandatory.
伴有腹水的肝硬化患者肾功能不全或急性肾损伤(AKI)的急性发作大多由急性事件引起。稳定腹水肝硬化患者中未诱发 AKI 的患病率尚不清楚。本研究的目的是确定(i)稳定伴有腹水的肝硬化患者中未诱发 AKI 的患病率,以及(ii)其发生的任何预测因素。
共纳入了 1115 例来自 3 项先前的 satavaptan 与安慰剂随机对照试验的稳定肝硬化患者,这些患者存在轻度肝肾功能障碍,但腹水严重程度不同(A 组:需要利尿剂但不需要行腹腔穿刺放液的腹水;B 组:需要频繁行腹腔穿刺放液的腹水;C 组:难治性腹水)。当在 48 小时内血清肌酐升高≥0.3mg/dL 或血清肌酐升高≥50%,且根据血清肌酐倍数进行分期时,诊断为 AKI。在筛选和 satavaptan 研究的随机分组时,最多测量 2 次血清肌酐水平,两次测量时间相隔 7 天以内,且无急性干预事件。
总体上未诱发 AKI 的患病率为 1.8%,且随着腹水严重程度的增加而升高。95%的病例为 1 期,进展率为 15%,3 例进展为 1 型急性肝肾综合征。腹水严重程度是未诱发 AKI 发展的最强预测因素,但不能预测总体死亡率。
尽管基线肝肾功能障碍轻微,但随着腹水严重程度的增加 AKI 的患病率增加,提示这些患者必须频繁监测肾功能。